Mr. Smith joined Assertio as president, chief executive officer (CEO) and director in May 2020. He previously served as president, CEO and a member of the board of directors of Zyla Life Sciences from October 2019 through the merger with Assertio. With more than 25 years of pharmaceutical, medical device and biotechnology leadership, he has a long track record of building companies and achieving commercial and business development excellence while maintaining a focus on patient access to differentiated products. Before joining Zyla, from 2017 through February 2019, Mr. Smith, served as CEO and a director of Iroko Pharmaceuticals Inc., a privately-owned pharmaceutical company, from which the Company purchased five products in early 2019. During the period October 2014 through June 2015, Mr. Smith served as the chief commercial officer of Ophthotech Corporation, a biopharmaceutical company focused on developing novel therapeutics to treat ophthalmic diseases. In addition, he has held a variety of senior commercial and marketing roles at organizations including Horizon Therapeutics plc, a public biopharmaceutical company focused on rare and rheumatic diseases, and Abbott, a public healthcare products company. Mr. Smith serves as a director for BVI, a TPG Ophthalmology company and for Vault Nano, a UCLA Biotech in Immuno-Oncology and Virology. Mr. Smith received his bachelor’s degree from Norwich University.
Mr. Peisert has served as senior vice president and chief financial officer since December 2018. Mr. Peisert joined Assertio as vice president, business development in September 2017 and was appointed senior vice President, business development in August 2018. Most recently he served in the position of vice president of Concordia International Corp.’s US Legacy Pharmaceuticals business where he had full P&L responsibility for the business unit. Prior to this, he was vice president, business development for Concordia and was responsible for executing on the strategic M&A plan. From 2008 to 2012, Mr. Peisert was director of finance and business development for Marathon Pharmaceuticals, a privately held specialty pharmaceutical company. Prior to entering the pharmaceutical industry, he was a healthcare equity analyst and portfolio manager for Magnetar Capital and UBS O’Connor and began his career as an auditor for Price Waterhouse Coopers. Mr. Peisert holds a bachelor’s of science in business with an emphasis on accounting from the University of Minnesota.
Ms. Timmins became the General Counsel upon the close of the merger with Zyla Life Sciences in May 2020. Since April 2016, she was with Zyla and most recently served as senior vice president, general counsel and secretary. Prior to joining Zyla, Ms. Timmins served in positions of increasing responsibility at Aramark, a food service, facilities, and uniform services provider to clients in fields including education, healthcare, business, corrections and leisure, for more than 12 years. Her most recent position at Aramark was vice president, associate general counsel and assistant secretary. Ms. Timmins received her B.A. in Government and Economics from the University of Notre Dame and her J.D. from the William and Mary School of Law.
Ms. Longoria joined Assertio as Vice President, Human Resources in May 2020. She brings over 18 years of global human resources leadership to this role. Most recently, she worked at Abbott, a Fortune 100 diversified healthcare company, as head of human resources for transfusion medicine and informatics, two global divisions within the diagnostics segment. Prior to this role, Ms. Longoria led the HR integration for one of the largest acquisitions in the history of Abbott. She has held various other worldwide human resources leadership positions for other operating businesses within Abbott throughout her career. Ms. Longoria received a bachelor of business administration in human resources management from the University of Wisconsin – Whitewater.
Dr. Strobeck joined Assertio through the merger with Zyla Life Sciences and became the chief operating officer (COO) in May 2020. Previously at Zyla he was the executive vice president and COO, a position he held since October 2015. He first joined Zyla in February 2014 as chief business officer (CBO). Previously Dr. Strobeck was president and CEO of Corridor Pharmaceuticals which he successfully sold to AstraZeneca and CBO of Topaz Pharmaceuticals which he sold to Sanofi Pasteur. Dr. Strobeck was CBO at Trevena Inc., and vice president of business development at GlaxoSmithKline. Before working at these healthcare companies, Dr. Strobeck was a venture capitalist at SR One Ltd., the wholly owned venture capital arm of GSK and Euclid SR Partners. Dr. Strobeck earned a Ph.D. in pharmacology and cell biophysics from the University of Cincinnati, completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania and received his bachelor’s degree from St. Lawrence University.